Biosimilars, also known as follow on biologics, are complex biotechnology drugs that are similar, but not identical, to original biologic drug forms, and represent potential lower cost versions that may improve access. Yet biologics and their biosimilar forms have a key safety concern: unwanted immunogenicity. Emerging markets have tremendous interest in biosimilars, but are at a tipping point: they are moving from developing country concerns (e.g., communicable disease) to developed country needs (e.g., cancer therapies) that require biologic drugs. Production, however, is at lower than current Good Manufacturing Practice levels standard in highly-regulated markets. Emerging market public-private partnerships between public agencies, local producers, and global pharmaceutical firms, can incentivize biosimilar production at higher quality levels than required for local markets as well as position themselves for entry into developed markets. Public health goals can be reached while increasing economic opportunities in these markets to benefit global health.
Liang, B.A. (2007) Regulating follow-on biologics. Harvard Journal on Legislation 44:363-471.
Baiese, B.A., Lee, E.H., Toscani, M., Silverman, E. (2010) Drug Pipeline Loses Pressure. Managed Care 19(8):23-6.
Comer, B. (2011) Biosimilars Spend to Reach /$2.5 Bln by 2015: IMS. PharmExecutive May 18. http://blog.pharmexec.com/2011/05/18/biosimilars-spend-to-reach-2-5-bln-by-2015-ims/, accessed Mar. 11, 2012.
Baiese, B.A., Lee, E.H., Toscani, M. (2011) Follow-on Biologics & Biosimilars Literature Review: The Current Landscape and Implications of Recent Healthcare Legislation for the U.S. Market. Specialty Pharma Journal http://www.specialtypharmajournal.com/index.php?option=com_content&view=article&id=2816:follow-on-biologics-a-biosimilars-literature-review-the-current-landscape-and-implications-of-recent-healthcare-legislation-for-the-us-market-&catid=425:catbiosimilars&Itemid=845, accessed Mar. 4, 2012.
Biosimilars in Emerging Markets. (2011) Biosimilar News Sept. 5. http://www.biosimilarnews.com/biosimilars-in-emerging-markets, accessed Feb. 28, 2012.
Chamberlain, P. (2002) Immunogenicity of therapeutic proteins: Part 1: Causes and clinical manifestations of immunogenicity. Regulatory Review 5:4-9.
Maheshwari, S. (2011) Global biosimilars marketâ€”a myriad of promises. Pharma Phorum. Sept. 22. http://www.pharmaphorum.com/2011/09/22/global-biosimilars-market-a-myriad-of-promises/, accessed Jan 31, 2012.
DePalma, A. (2011) Pharma forecasting: Stress-testing the business case for biosimilars. Eyeforpharma, Sept. 15. http://social.eyeforpharma.com/forecasting/pharma-forecasting-stress-testing-business-case-biosimilars, accessed Mar. 3, 2012.
First biosimilar drug gets EU market authorization. (2006) EurActiv Apr. 21. http://www.euractiv.com/health/biosimilar-drug-gets-eu-market-authorisation/article-154524, accessed Mar. 11, 2012.
Shuster, M.J., Farmer-Koppenol, P.F. (2012) A comparison of US and EU Biosimilars Regime. Mar. 1. http://www.mondaq.com/unitedstates/x/162212/Life+Sciences+Biotechnology/A+Comparison+Of+US+And+EU+Biosimilars+Regimes, accessed Mar. 4, 2012.
IMAP. (2011) Pharmaceutical & Biotech Industry Global Reportâ€”2011. http://www.imap.com/imap/media/resources/IMAP_PharmaReport_8_272B8752E0FB3.pdf, accessed Mar. 2, 2012.
Liang, B.A., Mackey, T. Emerging Patient Safety Issues Under Healthcare Reform: Follow On Biologics and Immunogenicity. (2011) Therapeutics and Clinical Risk Management 7:483-489.
US Food and Drug Administration. (2012) Guidance for Industry: Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009, Draft Guidance. Mar. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM273001.pdf, accessed Mar. 10, 2012.
Buse, K., Harmer, A.M. (2007) Seven habits of highly effective global publicâ€“private health partnerships: Practice and potential. Social Science & Medicine 64:259-271.
Mackey, T.K., Liang, B.A. (2011) Promoting Online Drug Safety: Using Publicâ€“Private Partnerships to Deter Illicit Online Drug Sales. Journal of Commercial Biotechnology 17(3):266-271.
Liang, B.A. (2011) Global Governance: Promoting Biodiversity and Protecting Indigenous Communities Against Biopiracy. Journal of Commercial Biotechnology 17(3):248-253.
Liang, B.A. (2011) Public-Private Partnerships in Global Health. Journal of Commercial Biotechnology 17(3):230-232.
Lin, R.J. (2011) The Biological Response to Biologics. Science Translational Medicine 3(80) 27:80ec61.
Hermeling, S., Crommelin, D.J.A., Schellekens, H., Jiskoot, W. (2004) Structure-immunogenicity relationships of therapeutic proteins. Pharmaceutical Research 21:897-903.
Lusher, J.M., Scharrer, I. (2009) Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer. International Journal of Hermatology 90(4): 446-54.
Bartelds, G.M., Krieckaert, C.L.M., Nurmohamed, M.T., et al. (2011) Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up. JAMA 305(14):1460-1468.
Grossberg, S.E., Oger, J., Grossberg, L.D., Gehchan, A., Klein, J.P. (2011) Frequency and Magnitude of Interferon Î² Neutralizing Antibodies in the Evaluation of Interferon Î² Immunogenicity in Patients with Multiple Sclerosis. Journal of Interferon and Cytokine Research 31(3): 337-344.
Bennett, C.L., Cournoyer, D., Carson, K.R., et al. (2005) Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 106(10):3343-7.
Schellekens, H., Jiskoot, W. (2006) Eprex-associated pure red cell aplasia and leachates. Nature Biotechnology 24:613-614.
Locatelli, F., Roger, S. (2006) Comparative testing and pharmacovigilance of biosimilars. Nephrology Dialysis Transplantation 21 (suppl 5): v13-v16.
Rader, R.A. (2011) Nomenclature of New Biosimilars Will Be Highly Controversial. BioProcess International. June. http://www.biopharma.com/biopharmacopeia/BPI_Biosimilars_article_6.2011.pdf, accessed Mar. 11, 2012.
Jayakumar, P.B. (2010) Indian pharma market on steroid-like growth. Business Standard (India), Oct. 6. http://www.business-standard.com/india/printpage.php?autono=410369&tp=, accessed Mar. 13, 2012.
Purcell, M., Leuchten, M., Bourdot, B., Dulac III, E.J. (2012) European Pharmaceuticals: Biosimilars move a step closer to reality. Barclays Capital Equity Research. 10 Mar. London: Barclays Capital.
Bourgoin, A.F. (2011) What You Need to Know about the Follow-On Biologic Market in the U.S.: Implications, Strategies, and Impact. Jan. http://thomsonreuters.com/content/science/pdf/ls/newport-biologics.pdf, accessed Jan. 31, 2012.
Mintz, C. (2009) Commercializing Biosimilars; Who Will Dominate the Market? Life Science Leader. Oct. http://www.lifescienceleader.com/index.php?option=com_jambozine&layout=article&view=page&aid=3886, accessed Jan. 31, 2012.
Mody, R., Varshney, B., Patankar, D. (2010) Understanding variation in biosimilars: Correlation with risk and regulatory implications. International Journal of Risk Safety Medicine 22:27-40.
Food and Drug Administration Amendments Act of 2007, Pub. L. 110-85 (2007).
Minz, C. (2009) An Update Regarding Follow-On Biologics. Life Sci Leader. July. http://www.lifescienceleader.com/index.php?option=com_jambozine&layout=article&view=page&aid=3855, accessed Mar. 4, 2012.
Looney, W. (2010) Biosimilars: The Decadeâ€™s Most Disruptive Technology. Pharm Executive Sept. 22. http://blog.pharmexec.com/2010/09/22/biosimilars-this-decades-most-disruptive-technology/, accessed Mar. 4, 2012.
Institute for Safe Medication Practices. (2012) ISMPâ€™s List of High-Alert Medications. http://www.ismp.org/Tools/highalertmedications.pdf, accessed Mar. 12, 2012.
Staton, T. (2012) Merck gains traction in Brazil with joint venture. FiercePharma. Mar. 15. http://www.fiercepharma.com/story/merck-gains-traction-brazil-joint-venture/2012-02-15, accessed Mar. 3, 2012.
Pfizer buys right to insulin biosimilars in $350 million deal with Indiaâ€™s Biocon. (2010) The Pharma Letter. Oct. 19. http://www.thepharmaletter.com/file/99188/pfizer-buys-rights-to-insulin-biosimilars-in-350-million-deal-with-indias-biocon.html, accessed Mar. 4, 2012.
Staton, T. (2011) Amgen beefs up Brazil with $126 million deal. FiercePharma. Apr. 11. http://www.fiercepharma.com/story/amgen-beefs-brazil-215m-deal/2011-04-11, accessed Mar. 2, 2012.
Mackey, T., Liang, B.A. (2012) Integrating Biodiversity Management and Indigenous Biopiracy Protection to Promote Environmental Justice and Global Health. American Journal of Public Health; In press.
Mackey, T., Liang, B.A. (2011) The Global Counterfeit Drug Trade: Patient Safety and Public Health Risks. Journal of Pharmaceutical Sciences 100(11):4571-4579.
Liang, B.A. (2008) A Dose of Reality: Promoting Access to Pharmaceuticals. Wake Forest Intellectual Property Law Journal 8(3):301-386.
Liang, B.A. (2008) Pigs, Drugs, and Terrorists. Patient Safety and Quality Healthcare 5(6):10-12.
Liang, B.A. (2006) Fade to Black: Importation and Counterfeit Drugs. American Journal of Law & Medicine 32:279-323.
Liang, B.A., Mackey, T. (2012) Vaccine Shortages and Suspect Online Pharmacy Sellers. Vaccine 30(2):103-105.
Liang, B.A., Mackey, T. (2012) Online Availability and Safety of Drugs in Shortage: A Descriptive Study of Internet Vendor Characteristics. Journal of Medical Internet Research 14(1):e27 doi:10.2196/jmir.1999.
Unless specified by prior arrangement, the author agrees to the following terms and assurances:
- For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
- I/we further give to the following assurances
- I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
- I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
- To the best of my/our knowledge, all the facts in the contribution are true and accurate;
- The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
- Nothing in the contribution is obscene or libellous;
- Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
- I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).